Human kinase proteins and polynucleotides encoding the same

Details Human kinase proteins and polynucleotides encoding the same Human kinase proteins and polynucleotides encoding the same

2003-05-27

2004-10-19

Monshipouri, Maryam (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Transferase other than ribonuclease

C530S350000, C453S037000, C453S037000, C453S037000

Reexamination Certificate

active

06806073

ABSTRACT:

INTRODUCTION
The present invention relates to the discovery, identification, and characterization of novel human polynucleotides encoding proteins that share sequence similarity with animal kinases. The invention encompasses the described animals that either lack or over express the disclosed sequences, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed genes that can be used for diagnosis, drug screening, clinical trial monitoring and the treatment of physiological disorders.
BACKGROUND OF THE INVENTION
Kinases mediate phosphorylation of a wide variety of proteins and compounds in the cell. Along with phosphatases, kinases are involved in a range of regulatory pathways. Given the physiological importance of kinases, they have been subject to intense scrutiny and are proven drug targets.
SUMMARY OF THE INVENTION
The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with animal kinases, including, but not limited to calcium/calmodulin-dependant protein kinases and serine/threonine protein kinases. As such, the novel polynucleotides encode a novel kinase family having homologues and orthologs across a range of phyla and species.
The novel human polynucleotides described herein, encode open reading frames (ORFs) encoding proteins of 385 or 356 amino acids in length (see SEQ ID NOS: 2 and 4 respectively).
The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof that compete with native NHPs, NHP peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP polynucleotides (e.g., expression constructs that place the described sequence under the control of a strong promoter system). The present invention also includes both transgenic animals that express a NHP transgene, and NHP “knock-outs” (which can be conditional) that do not express a functional NHP.
Also encompassed by the present invention are novel protein constructs engineered in such a way that they facilitate transport of the NHP to the target site, to the desired organ, across the cell membrane and/or to the nucleus where the NHP can exert its function activity. This goal may be achieved by coupling of the NHP to a cytokine or other ligand that would direct the NHP to the target organ and facilitate receptor mediated transport across the membrane into the cytosol. Conjugation of NHPs to antibody molecules or their Fab fragments could be used to target cells bearing a particular epitope. Attaching the appropriate signal sequence to the NHP would also transport the NHP to the desired location within the cell. Alternatively targeting of NHP or its nucleic acid sequence might be achieved using liposome or lipid complex based delivery systems. Such technologies are described in
Liposomes: A Practical Approach
, R. R. C. New, Ed., Oxford University Press, New York and in U.S. Pat. Nos. 4,594,595, 5,459,127, 5,948,767 and 6,110,490 and their respective disclosures which are herein incorporated by reference in their entirety.
Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP product activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.


REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4594595 (1986-06-01), Struckman
patent: 4631211 (1986-12-01), Houghten
patent: 4689405 (1987-08-01), Frank et al.
patent: 4713326 (1987-12-01), Dattagupta et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5252743 (1993-10-01), Barrett et al.
patent: 5424188 (1995-06-01), Fodor et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5556752 (1996-09-01), Lockhart et al.
patent: 5700637 (1997-12-01), Southern
patent: 5744305 (1998-04-01), Fodor et al.
patent: 5817479 (1998-10-01), Au-Young et al.
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 5837458 (1998-11-01), Minshull et al.
patent: 5869336 (1999-02-01), Meyer et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5948767 (1999-09-01), Scheule et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6110490 (2000-08-01), Thierry
Bird et al, 1988, “Single-Chain Antigen-Binding Proteins”, Science 242:423-426.
Bitter et al, 1987, “Expression and Secretion Vectors for Yeast”, Methods in Enzymology 153:516-544.
Colbere-Garapin et al, 1981, “A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells”, J. Mol. Biol. 150:1-14.
Gautier et al, 1987, “&agr;-DNA IV:&agr;-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding”, Nucleic Acids Research 15(16):6625-6641.
Greenspan et al, 1993, “Idiotypes: structure and Immunogenicity”, FASEB Journal 7:437-444.
Huse et al, 1989, “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”, Science 246:1275-1281.
Inoue et al, 1987, “Sequence-dependant hydrolysis of RNA using modified oligonucleotide splints and R Nase H”, FEBS Letters 21 5(2):327-330.
Inoue et al, 1987, “Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides”, Nucleic Acids Research 15(15):6131-6149.
Ionuye & Ionuye, 1985, “Up-promoter mutations in the lpp gene ofEscherichia coli”, Nucleic Acids Research 13(9):3101-3110.
Janknecht et al, 1991, “Rapid and effecient purification of native histidine-tagged protein expressed by recombinant vaccinia virus”, PNAS 88:8972-8976.
Kohler & Milstein, 1975, “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature 256:495-497.
Logan et al, 1984, “Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection”, Proc. Natl. Acad. Sci. USA 81:3655-3659.
Lowy et al, 1980, “Isolation of Transforming DNA: Cloning the Hamster aprt Gene”, Cell 22:817-823.
Morrison et al, 1984, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc. Natl. Acad. Sci. USA 81:6851-6855.
Mulligan & Berg, 1981, “Selection for animal cells that express theEscherichia coligene coding for xanthine-guanine phosphoribosyltransferase”, Proc. Natl. Acad. Sci. USA 78(4):2072-2076.
Neuberger et al, 1984, “Recombinant antibodies possessing novel effector functions”, Nature 312:604-608.
Nisonoff, 1991, “Idiotypes: Concepts and Applications”, J. of Immunology 147:2429-2438.
O'Hare et al, 1981, “Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase”, Proc. Natl. Acad. Sci. USA 78(3):1527-1531.
Ruther et al, 1983, “Easy identification of cDNA clones”, EMBO Journal 2(10):1791-1794.
Santerre et al, 1984, “Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells”, Gene 30:147-156.
Sarin et al, 1988, “Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates”, Proc. Natl. Acad. Sci. USA 85:7448-7451.
Smith et al, 1983, “Molecular Engineering of theAutographa californicaNuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene”, J. Virol. 46(2):584-593.
Stein et al, 1988, “Physiochemical properties of phosphorothloate oligodeoxynucleo

Affiliated with

Also associated with

Rating

Human kinase proteins and polynucleotides encoding the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human kinase proteins and polynucleotides encoding the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human kinase proteins and polynucleotides encoding the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3270458